Although not officially indicated in Canada as add-on therapy, acarbose is of benefit when combined with other oral agents. The combination of acarbose with a sulphonylurea is particularly advantageous because the acarbose attenuates the sulphonlyurea-induced hyperinsulinemia and weight gain. Use of acarbose with metformin may be a somewhat less attractive option since the gastrointestinal intolerance associated with both agents may be additive, and weight gain and hyperinsulinemia do not occur during metformin therapy. You will always be given purchase Tavist and will enjoy paying less money.
Commercial availability of an alpha-glucosidase inhibitor provides an additional, unique therapeutic option for the management of NIDDM. This is a welcome development because the majority of the NIDDM population is not adequately controlled with current drug therapy and emphasis is now being placed on the need for more aggressive pharmacological treatment of NIDDM. The Diabetes Control and Complications Trial, together with recently published epidemiological evidence, strongly suggest a linear relationship between HbA1c level and the risk of microvascular and macrovascular complications. Thus, even a modest reduction of 0.75% to 1.0% in HbA1c, which can be expected when acarbose is used alone or is added to pre-existing oral monotherapy, should help to reduce the morbidity prevalent in NIDDM. In addition, acarbose may have a role in preventing the progression to overt diabetes (NIDDM) in those with impaired glucose tolerance (‘prediabetes’). Results of a pilot study in these individuals indicate that acarbose can reduce the insulin resistance that is an important factor in development of NIDDM.